Structure Identification and Risk Assurance of Unknown Impurities in Pramipexole Oral Drug Formulation

Impurities compounds in any pharmaceutical product or drug substance are inevitable from a chemistry point of view. The quality and safety of a pharmaceutical product are also significantly affected by these impurities content; therefore, impurities need to be identified and characterized through th...

Full description

Saved in:
Bibliographic Details
Main Authors: Raymond R. Tjandrawinata, Antonius H. Cahyana, Ajeng O. Nugroho, Indra K. Adi, Joseph S. R. Talpaneni
Format: Article
Language:English
Published: Wiley 2024-01-01
Series:Advances in Pharmacological and Pharmaceutical Sciences
Online Access:http://dx.doi.org/10.1155/2024/5583526
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832553054602264576
author Raymond R. Tjandrawinata
Antonius H. Cahyana
Ajeng O. Nugroho
Indra K. Adi
Joseph S. R. Talpaneni
author_facet Raymond R. Tjandrawinata
Antonius H. Cahyana
Ajeng O. Nugroho
Indra K. Adi
Joseph S. R. Talpaneni
author_sort Raymond R. Tjandrawinata
collection DOAJ
description Impurities compounds in any pharmaceutical product or drug substance are inevitable from a chemistry point of view. The quality and safety of a pharmaceutical product are also significantly affected by these impurities content; therefore, impurities need to be identified and characterized through the use of appropriate analytical methods. Pramipexole is a nonergot dopamine agonist used to treat various Parkinson’s disease symptoms. Two unknown impurities were detected from a pramipexole dihydrochloride solid dosage form. These impurities were identified and characterized using ultra-performance liquid chromatography coupled with high-resolution mass spectroscopy (UPLC-HRMS). These impurities were found to be enriched when mannitol existed in the formulation. The structure and mechanism involved in the existence of the impurities were proposed. Furthermore, observation of the binding affinity potential risk of these impurities to the pramipexole receptor has also been demonstrated through molecular docking and molecular dynamics simulation study. The binding energy result showed that pramipexole interaction with dopamine receptors D2 and D3 was higher than pramipexole mannose adduct and pramipexole ribose adduct.
format Article
id doaj-art-482e765e0817401d8063417db71ad300
institution Kabale University
issn 2633-4690
language English
publishDate 2024-01-01
publisher Wiley
record_format Article
series Advances in Pharmacological and Pharmaceutical Sciences
spelling doaj-art-482e765e0817401d8063417db71ad3002025-02-03T05:57:03ZengWileyAdvances in Pharmacological and Pharmaceutical Sciences2633-46902024-01-01202410.1155/2024/5583526Structure Identification and Risk Assurance of Unknown Impurities in Pramipexole Oral Drug FormulationRaymond R. Tjandrawinata0Antonius H. Cahyana1Ajeng O. Nugroho2Indra K. Adi3Joseph S. R. Talpaneni4Atma Jaya Catholic University of IndonesiaDepartment of ChemistryDepartment of ChemistryDexa Development CentreDexa Development CentreImpurities compounds in any pharmaceutical product or drug substance are inevitable from a chemistry point of view. The quality and safety of a pharmaceutical product are also significantly affected by these impurities content; therefore, impurities need to be identified and characterized through the use of appropriate analytical methods. Pramipexole is a nonergot dopamine agonist used to treat various Parkinson’s disease symptoms. Two unknown impurities were detected from a pramipexole dihydrochloride solid dosage form. These impurities were identified and characterized using ultra-performance liquid chromatography coupled with high-resolution mass spectroscopy (UPLC-HRMS). These impurities were found to be enriched when mannitol existed in the formulation. The structure and mechanism involved in the existence of the impurities were proposed. Furthermore, observation of the binding affinity potential risk of these impurities to the pramipexole receptor has also been demonstrated through molecular docking and molecular dynamics simulation study. The binding energy result showed that pramipexole interaction with dopamine receptors D2 and D3 was higher than pramipexole mannose adduct and pramipexole ribose adduct.http://dx.doi.org/10.1155/2024/5583526
spellingShingle Raymond R. Tjandrawinata
Antonius H. Cahyana
Ajeng O. Nugroho
Indra K. Adi
Joseph S. R. Talpaneni
Structure Identification and Risk Assurance of Unknown Impurities in Pramipexole Oral Drug Formulation
Advances in Pharmacological and Pharmaceutical Sciences
title Structure Identification and Risk Assurance of Unknown Impurities in Pramipexole Oral Drug Formulation
title_full Structure Identification and Risk Assurance of Unknown Impurities in Pramipexole Oral Drug Formulation
title_fullStr Structure Identification and Risk Assurance of Unknown Impurities in Pramipexole Oral Drug Formulation
title_full_unstemmed Structure Identification and Risk Assurance of Unknown Impurities in Pramipexole Oral Drug Formulation
title_short Structure Identification and Risk Assurance of Unknown Impurities in Pramipexole Oral Drug Formulation
title_sort structure identification and risk assurance of unknown impurities in pramipexole oral drug formulation
url http://dx.doi.org/10.1155/2024/5583526
work_keys_str_mv AT raymondrtjandrawinata structureidentificationandriskassuranceofunknownimpuritiesinpramipexoleoraldrugformulation
AT antoniushcahyana structureidentificationandriskassuranceofunknownimpuritiesinpramipexoleoraldrugformulation
AT ajengonugroho structureidentificationandriskassuranceofunknownimpuritiesinpramipexoleoraldrugformulation
AT indrakadi structureidentificationandriskassuranceofunknownimpuritiesinpramipexoleoraldrugformulation
AT josephsrtalpaneni structureidentificationandriskassuranceofunknownimpuritiesinpramipexoleoraldrugformulation